Dianthus Therapeutics (NASDAQ:DNTH) Announces Quarterly Earnings Results, Beats Estimates By $0.04 EPS

Dianthus Therapeutics (NASDAQ:DNTH) released its earnings results on Tuesday. The company reported ($0.81) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.85) by $0.04, Zacks reports. Dianthus Therapeutics had a negative net margin of 1,250.32% and a negative return on equity of 21.68%.

Dianthus Therapeutics Trading Down 3.9 %

DNTH stock opened at $23.38 on Wednesday. The stock has a market cap of $691.98 million, a PE ratio of -9.35 and a beta of 1.82. Dianthus Therapeutics has a 12 month low of $18.13 and a 12 month high of $33.77. The company has a 50-day moving average price of $22.65 and a 200 day moving average price of $24.97.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on DNTH shares. Raymond James raised shares of Dianthus Therapeutics to a “moderate buy” rating in a research note on Thursday, December 12th. TD Cowen started coverage on Dianthus Therapeutics in a research report on Friday, December 20th. They set a “buy” rating for the company. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $40.00 target price on shares of Dianthus Therapeutics in a report on Wednesday. Seven investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $46.83.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.